Masimo CORP

Masimo Corporation has been acquired by Danaher Corporation, with shares converted to $180.00 cash per share.

Masimo Corporation's shareholders have overwhelmingly approved the merger agreement with Danaher Corporation, paving the way for the acquisition.

Masimo Corporation has filed supplemental disclosures to its definitive proxy statement regarding the pending merger with Danaher Corporation to address ongoing stockholder litigation.

Masimo Corporation has entered into a definitive agreement to be acquired by Danaher Corporation for $180.00 per share in cash, totaling approximately $9.9 billion.

Masimo Corporation announced preliminary Q4 and full-year 2025 financial results, showing robust revenue growth and non-GAAP EPS at the high end of guidance.

Masimo Corporation reaffirmed its 2025 financial guidance and announced long-range targets through 2028, emphasizing strategic growth in patient monitoring and innovation.

Masimo Corporation reports Q1 2026 revenue of $403.6 million and continues progress toward its pending acquisition by Danaher Corporation.

Masimo Corporation reported strong growth in its continuing healthcare operations for Q3 2025, but a significant net loss driven by the sale of its non-healthcare consumer business.

Masimo Corporation reports increased revenue and gross profit in its continuing healthcare operations, while navigating a significant loss from discontinued non-healthcare business due to impairment charges and ongoing complex litigations.

Masimo Corporation announces its Q1 2025 financial results, highlighted by a revenue increase and the strategic decision to sell its non-healthcare business to HARMAN International, while also addressing a recent cybersecurity incident.

Masimo Corporation's Q3 2024 results show a slight revenue increase and a net income decrease, alongside significant management changes.

Masimo Corporation's Q2 2024 results show a revenue increase driven by healthcare growth, offset by a decline in the non-healthcare segment, with overall net income remaining relatively flat.

Masimo Corporation filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.

Masimo Corporation's 2025 annual report highlights robust healthcare revenue growth, the planned sale of its non-healthcare business, and a definitive merger agreement with Danaher Corporation.

Masimo Corporation navigates leadership changes and strategic realignments while reporting a slight revenue increase but a significant net loss for fiscal year 2024, driven by impairment charges and legal expenses.

Masimo Corporation has filed an amendment to its 2023 annual report to include previously omitted information regarding directors, executive compensation, and other corporate governance matters.

Masimo Corporation updates its severance protection plan for a key executive and files its annual report, detailing financial results and strategic initiatives amidst a challenging economic landscape.

Director Darlene J. Solomon reports the disposal of Masimo Corporation common stock and RSUs following the company's acquisition by Danaher Corporation.

Director Timothy J. Scannell reports the disposal of Masimo Corporation common stock and RSUs following the company's acquisition by Danaher Corporation.

Director Wendy E. Lane reports the disposal of Masimo Corporation common stock and RSUs following the company's acquisition by Danaher Corporation.

Politan Capital Management reports the termination of forward sale contracts following the acquisition of Masimo Corporation by Danaher Corporation.

Politan Capital Management reports the disposal of its entire stake in Masimo Corporation following the company's acquisition by Danaher Corporation.

Masimo Corporation has completed its merger with Danaher Corporation, resulting in the cancellation of all outstanding common stock and restricted stock units for a cash payment of $180 per share.

Masimo Corporation's proxy statement reveals a year of significant changes, including a CEO transition, board realignment, and strategic initiatives focused on long-term growth and shareholder value.

Masimo is challenging the influence of proxy advisory firms ISS and Glass Lewis as Politan Capital Management seeks additional board seats.

Masimo Corporation updates stockholders on the 2024 Annual Meeting, addressing potential uncertainties related to Politan Capital Management's director nominations.

Masimo updates its website with a testimonial from a St. Luke's University Health Network executive, emphasizing the positive impact of Masimo's Patient SafetyNet on patient outcomes and quality data.

A high-stakes proxy battle at Masimo, pitting founder Joe Kiani against activist investor Quentin Koffey, culminates in a shareholder vote that could determine the company's future leadership and direction.

Masimo updates its website with letters of support for its CEO, Joe Kiani, as it faces a proxy battle ahead of the 2024 Annual Meeting of Stockholders.

Politan Capital Management has fully exited its position in Masimo Corp following the completion of a merger that converted all shares into $180.00 cash per share.

Pentwater Capital Management LP and Matthew Halbower have filed a Schedule 13G reporting a 6.1% beneficial ownership stake in Masimo Corp.

Barclays PLC has filed a Schedule 13G reporting a 5.54% beneficial ownership stake in Masimo Corp as of March 31, 2026.

Joe Kiani, a significant shareholder in Masimo Corporation, has filed an amended Schedule 13G, asserting beneficial ownership of 3,657,039 shares, representing 6.5% of the company's stock, while disputing his termination and the cancellation of certain equity awards.

BlackRock Portfolio Management LLC reports a 0.2% beneficial ownership stake in Masimo Corp as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Masimo Corp following an internal realignment.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 4.5% beneficial ownership stake in Masimo Corp common stock as of February 27, 2026.